Pharmaceutical Engineering Group, School of Pharmacy, Medical Biology Centre , Queen's University , Belfast BT9 , Northern Ireland.
Mol Pharm. 2018 Sep 4;15(9):3741-3754. doi: 10.1021/acs.molpharmaceut.7b00979. Epub 2018 Jul 30.
Pharmaceutical cocrystals have attracted increasing attention over the past decade as an alternative way to modify the physicochemical properties and hence improve the bioavailability of a drug, without sacrificing thermodynamic stability. Our previous work has demonstrated the viability of in situ formation of ibuprofen/isonicotinamide cocrystal suspensions within a matrix carrier via a single-step hot melt extrusion (HME) process. The key aim of the current work is to establish optimized processing conditions to improve cocrystal yield within extruded matrices. The solubility of each individual cocrystal component in the matrix carrier was estimated using two different methods, calculation of Hansen solubility parameters and Flory-Huggins solution theory using a melting point depression measurement method, respectively. The latter was found to be more relevant to extrusion cocrystallization because of the ability to predict miscibility across a range of temperatures. The predictions obtained from the F-H phase diagrams were verified using ternary extrusion processing. Temperatures that promote solubilization of the parent reagents during processing and precipitation of the newly formed cocrystal were found to be the most suitable in generating high cocrystal yields. The incorporation of intensive mixing/kneading elements to the screw configuration was also shown to significantly improve the cocrystal yield when utilizing a matrix platform. This work has shown that intensive mixing, in combination with appropriate temperature selection, can significantly improve the cocrystal yield within a stable and low viscosity carrier during HME processing. Most importantly, this work reports, for the very first time in the literature, the use of the F-H phase diagrams to guide the most appropriate HME processing window to drive higher cocrystal yield.
在过去的十年中,药物共晶作为一种改变药物物理化学性质并提高其生物利用度的替代方法,引起了越来越多的关注,而不会牺牲热力学稳定性。我们之前的工作已经证明了通过单步热熔挤出(HME)工艺在基质载体中原位形成布洛芬/异烟酰胺共晶悬浮液的可行性。目前工作的主要目标是建立优化的加工条件,以提高挤出基质中的共晶产率。使用两种不同的方法估计了每个共晶成分在基质载体中的溶解度,分别是 Hansen 溶解度参数的计算和使用熔点降低测量方法的 Flory-Huggins 溶液理论。由于能够预测在一系列温度下的混溶性,后者与挤出共晶化更相关。使用三元挤出加工验证了从 F-H 相图获得的预测。发现促进加工过程中母体试剂溶解和新形成共晶沉淀的温度最适合产生高共晶产率。还表明,在螺杆构型中加入强化混合/捏合元件,当利用基质平台时,可显著提高共晶产率。这项工作表明,强化混合与适当的温度选择相结合,可以在 HME 加工过程中稳定且低粘度的载体中显著提高共晶产率。最重要的是,这项工作首次报告了使用 F-H 相图来指导最合适的 HME 加工窗口,以提高共晶产率。